For a platform company with wide-ranging technology, the key early struggle is focusing. It is critical to prioritize a single program to generate near-term data and change the cost of capital before realizing the platform's full potential.
As an investor stepping into an interim CEO role, success hinges on leveraging long-standing relationships with the early team. Proactively building trust with newer employees through informal chats is also critical, proving personal connection trumps formal authority.
Yosemite's investment portfolio shows a bias towards "first in class" or potentially curative "last in class" therapies. This indicates a higher tolerance for innovation risk, betting on novel modalities and groundbreaking science over safer, incremental advances.
Yosemite provides unrestricted grants to academic scientists, de-risking novel research and building relationships. This early support creates a unique deal flow engine, leading to investment opportunities in companies that later spin out from this foundational work.
Unlike traditional biotech VCs, Yosemite allocates a quarter of its fund to digital health. This reflects its mission to reduce cancer mortality across the entire patient journey, funding solutions for pricing transparency, financial toxicity, and post-approval care.
While focused on oncology, Yosemite's portfolio company Tune Therapeutics is using epigenetic editing to develop a functional cure for Hepatitis B. This is a strategic cancer play, as chronic Hepatitis B is the leading global cause of liver cancer.
Yosemite's oncology focus stems from Reed Jobs' experience with his father Steve Jobs' pancreatic cancer. However, the firm deliberately adopts a broad, pan-cancer investment strategy, recognizing the interconnectedness of cancer biology across different tissue types.
After serving as interim CEO at portfolio company Tune Therapeutics, VC Dan McHugh gained a profound appreciation for operational challenges. He now emphasizes deeper diligence on areas like manufacturing process development, which he previously understood only at a surface level.
While biotech hubs like Boston offer a larger talent pool, companies in emerging hubs may benefit from higher employee retention. With fewer local competitors, top talent is less likely to be poached, creating more stable teams, a trade-off investors consider.